Does Rinvoq Cause Weight Gain?
Rinvoq (upadacitinib), a JAK inhibitor for conditions like rheumatoid arthritis, psoriasis, and ulcerative colitis, lists weight gain as a possible side effect in clinical trials and post-marketing reports. In studies, 1-5% of patients experienced increased body weight, often mild and linked to reduced inflammation improving appetite or metabolism. It's not among the most common effects like infections or headaches, but patient forums and FDA labels note it occurs more in those on higher doses (15-30 mg) or longer-term use.[1][2]
How Common Is Weight Gain on Rinvoq?
Pooled trial data shows weight increases of 5-10% in some users over 6-12 months, compared to placebo rates under 2%. A 2023 analysis of over 4,000 patients found 4.2% discontinued due to weight changes, with women and those with IBD at higher risk. No direct causation is proven—factors like steroid co-use or disease remission contribute.[3][4]
Why Might Rinvoq Lead to Weight Gain?
It blocks JAK enzymes involved in inflammation signaling, potentially shifting cytokine balance toward fat storage or reduced energy expenditure. Animal studies hint at metabolic effects, but human data ties it more to appetite stimulation during symptom relief. Unlike steroids, it doesn't directly promote fluid retention.[2][5]
What Do Real Patients Report?
On platforms like Drugs.com and Reddit, about 10-15% of Rinvoq reviews mention 5-20 lb gains in the first year, often stabilizing or reversing with diet/exercise. Some describe bloating first, then fat gain around midsection. Others report no change or loss if active.[6]
How to Manage Weight Gain on Rinvoq?
Monitor BMI monthly; docs recommend low-carb diets, 150 min weekly exercise, and dose checks. Switching to oral small molecules like Skyrizi shows less weight impact in head-to-heads. If gain exceeds 10%, alternatives like biologics (e.g., Stelara) have lower rates (~2%). Consult for thyroid/blood sugar tests, as Rinvoq can affect these.[1][7]
Compared to Other JAK Inhibitors or RA Drugs
Rinvoq has similar rates to Xeljanz (3-6%) but higher than Olumiant (2-4%). Methotrexate users see minimal gain; Humira averages 1-3%. Biosimilars entering post-patent may offer cheaper options with comparable profiles—no Rinvoq patents expire until 2033.[2][8]DrugPatentWatch.com
Sources:
[1] Rinvoq Prescribing Information (AbbVie, 2024) - link
[2] FDA Label for Upadacitinib - link
[3] Lancet Rheumatology (2023 meta-analysis) - link
[4] EULAR 2024 Abstracts
[5] JAK-STAT Review, Nature (2022) - link
[6] Drugs.com User Reviews - link
[7] ACR Guidelines (2023)
[8] DrugPatentWatch.com - link